

Press Release

Apogenix to Present at AACR Virtual Annual Meeting II

Heidelberg, Germany, June 17, 2020 – Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the [AACR Virtual Annual Meeting II](#), which takes place online from June 22-24, 2020. Participation will be free to everyone, but registration is required to view the meeting.

Presentation #1076 – June 23, 9:00-11:00 am EDT: “Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies” – Christian Gieffers, Ph.D., VP Preclinical Development

Poster Presentations:

- **Poster #4460 – Poster Session “Combination Immunotherapies 3”, June 22-24:** “Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting” – Meinolf Thiemann, Ph.D., VP Protein Analytics
- **Poster #4529 – Poster Session “Immunomodulatory Agents and Interventions 1”, June 22-24:** “Neutralization of pro-apoptotic CD95L by Asunercept/APG101 does not impair anti-tumor immune responses” – Christian Merz, Ph.D., Head of Cellular Analytics/Biomarker Development

About Apogenix

Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer. In addition, it is evaluating the potential of its lead immunotherapy candidate asunercept in viral infections, such as COVID-19. The company’s pipeline of immunotherapy drug candidates targets different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the anti-tumor immune response in cancer patients and reducing lymphopenia and inflammatory cell death in patients with viral infections. Checkpoint inhibitor asunercept, the company’s lead immunotherapy candidate, is in late-stage clinical development with PRIME (PRiority MEDicines) designation by the European Medicines Agency for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, and 4-1BB receptor agonists for cancer immunotherapy. The TRAIL receptor agonist program was outlicensed to AbbVie. AbbVie is conducting a phase I trial with TRAIL receptor agonist ABBV-621 in patients suffering from solid tumors, non-Hodgkins’s lymphoma, or acute myeloid leukemia.

Contacts

Peter Willinger, CFO
Jennifer Mogk, PR Manager
Apogenix AG
Phone: +49 6221 58608-0
E-Mail: contact@apogenix.com
Web: www.apogenix.com

Media Contacts

Katja Arnold
Andreas Jungfer
MC Services AG
Phone: +49 89 210228-0
E-Mail: apogenix@mc-services.eu